21

KeyMed Biosciences IncHKG 2162 Stock Report

Last reporting period 30 Jun, 2022

Updated 01 Nov, 2024

Last price

Market cap $B

1.255

Small

Exchange

XHKG - Hong Kong Exchange

2162.HK Stock Analysis

21

Uncovered

KeyMed Biosciences Inc is uncovered by Eyestock quantitative analysis.

Market cap $B

1.255

Dividend yield

Shares outstanding

277.92 B

Keymed Biosciences, Inc. is an investment holding company, which engages in the discovery and development of biological therapies in the autoimmune and oncology therapeutic areas. The company is headquartered in Chengdu, Sichuan. The company went IPO on 2021-07-08. The firm focuses on the independent discovery and development of innovative biological therapies that address underserved medical needs in the autoimmune and oncology therapeutic areas. The firm has mastered in-house drug discovery and development technologies, including an innovative antibody discovery platform and a proprietary novel T cell engager (nTCE) bispecific antibody platform. The firm has also established a fully integrated platform covering the key functions of biopharmaceutical development. The firm's main products include CM310, CM326 and CMG901.

View Section: Eyestock Rating